Investigation of hepatitis B virus prevalence and reactivation frequency in malignancy patients administering chemotherapy

Authors

  • Muhammet Cengiz Clinic of Internal Medicine, Hasan Calik State Hospital, Malatya, Turkey
  • Yuksel Seckin Department of Gastroenterology, Faculty of Medicine, Inonu University, Malatya, Turkey
  • Yasir Furkan Cagin Department of Gastroenterology, Faculty of Medicine, Inonu University, Malatya, Turkey
  • Ayse Nuransoy Cengiz Department of Internal Medicine, Faculty of Medicine, Inonu University, Malatya, Turkey

Keywords:

Chemotherapy, Hepatitis B, reactivation, screening

Abstract

Aim: This study aimed to investigate the frequency at which physicians test hepatitis B virus (HBV) serology before treatment and the rate of hepatitis B virus reactivation (HBVr) after treatment in patients undergoing chemotherapy (CT) due to a solid organ malignancy (SOM) or hematological malignancy (HM).
Materials and Methods: Baseline clinical feature, HBV serology, and liver function test data for 1275 patients ≥ 18 years of age who underwent CT for the first time due to various SOMs and HMs from 2015-2017 were obtained from the database and retrospectively analyzed. HBV serology was studied in 296 (201 HM, 95 SOM) of the 1275 patients retrieved from the database.
Results: The prevalence of HBV was 9.5% (121 patients). Only 49 (40.4%) HBV-positive patients had HBV DNA. Of those, 72 (59.5%) underwent prophylactic antiviral therapy. HBVr was detected in only 3 patients (1.5%), and all of those patients had HMs and were recommended oral antiviral therapy but did not.
Conclusion: In patients with SOMs, the screening rates of HBV serology, as well as prophylaxis and follow-up HMs were extremely low. Therefore, these patients should be screened for HBV serology and prophylactic treatment should be given when necessary for HBVr.

Downloads

Download data is not yet available.

Downloads

Published

2021-11-24

Issue

Section

Original Articles

How to Cite

1.
Investigation of hepatitis B virus prevalence and reactivation frequency in malignancy patients administering chemotherapy. Ann Med Res [Internet]. 2021 Nov. 24 [cited 2025 Feb. 19];28(11):2059-64. Available from: http://www.annalsmedres.org/index.php/aomr/article/view/3976